Liquid Biopsy Market

Liquid Biopsy Market : Increasing demand for faster, accurate and minimally invasive cancer diagnosis fuelling adoption of liquid biopsy procedures: Global Industry Analysis and Opportunity Assessment, 2016 - 2026

Ask The Analyst Customization Available Request Methodology

Introduction

Liquid biopsy is an advanced cancer diagnostic test that uses biofluids such as blood, CSF, plasma and urine for detecting cancer. The test can be used to detect cancer in early stages. It is a non-invasive diagnostic test that uses circulating nucleic acids, circulating tumour cells (CTC) and exosomes as a biomarker for diagnosis of cancer. In the body, aforementioned biomarkers are released into different body fluids by cancer cells. The test requires blood, urine and cerebral spinal fluid (CSF) samples for diagnosis of various cancers. Among all samples, blood sample is widely used for diagnosis of various cancers such as lung cancer, breast cancer and leukemia. Urine and CSF samples are used for diagnosis of prostate cancer and brain cancer respectively.

Market Value and Forecast

Global liquid biopsy market revenues are projected to expand at a CAGR of 21.7% during the forecast period 2016-2026 and a reach value of US$ 2,893.7 million by the end of 2026.

Market Dynamics

Growth of the global liquid biopsy market is mainly driven by increasing prevalence of cancer globally. Increasing prevalence of various cancers such as lung cancer, breast cancer and prostate cancer is expected to drive growth of the liquid biopsy test market over the forecast period. Other prominent growth factors include increasing preference of oncologists towards non-invasive diagnostic procedure for detecting cancer. However, cost and lower awareness regarding liquid biopsy tests are the major factor expected to restrain growth of global liquid biopsy market over the forecast period.

FDA approvals for various non-invasive diagnostic tests to detect cancer is set to define the regulatory landscape for liquid biopsy tests. Companies in the liquid biopsy market space are expected to invest more on test kits and cost containment procedures to provide innovative diagnostic solutions to the oncologists and physicians for detecting metastasis.

Market Segmentation by Marker Type

Based on marker type, the market has been segmented into circulating tumour Cells (CTCs), ctNA circulating tumour nucleic acids (ctNA), and exosomes.

Market Segmentation, by Sample Type

Based on sample type, the market has been segmented into blood, urine, and others (plasma, saliva, Cerebrospinal fluid). Blood sample type segment, is expected to create significant incremental opportunity in global liquid biopsy market over the forecast period.

Market Segmentation, by Disease Indication

Based on disease indication, the market has been segmented into lung cancer, gastrointestinal cancer, prostate cancer, breast cancer, colorectal, leukemia and others. Lung cancer, disease indication segment currently accounts for highest revenue as compared to other segments in the global liquid biopsy market. Whereas breast cancer and colorectal cancer, disease indication segments have been anticipated to contribute significant revenue in global liquid biopsy market over the forecast period.

Market Segmentation, by End User

Based on end user type, the market has been segmented into hospitals, cancer institutes, academic institutes and diagnostic centres. Cancer institute is the largest end user segment in terms of revenues and is expected to create significant incremental opportunity in global liquid biopsy market over the forecast period.

Key Regions

The global liquid biopsy market has been segmented into seven major regions: North America, Latin America, Western Europe, Eastern Europe, Asia Pacific excluding Japan (APEJ), Japan, and Middle East & Africa (MEA). In terms of value, North America is estimated to be the dominant market in 2016, which is expected to expand at a CAGR of 21.3% over the forecast period. APEJ is estimated to be the fastest growing markets in terms of revenue growth. APEJ liquid biopsy market is expected to register a CAGR of 25.5% over the forecast period. Lung cancer disease indication segment in the APEJ liquid biopsy market is expected to register a CAGR of 22.0% over the forecast period, with growth driven by increasing prevalence of lung cancer in the region.

liquid biopsy market

Key Players

Some key players in the global liquid biopsy market identified in this report are BIOCEPT, INC., Qiagen N.V., Trovagene, Inc., Janssen Global Services, LLC, MDxHealth SA, Natera, Inc., F. Hoffmann-La Roche Ltd., Silicon Biosystems, Pathway Genomics Corporation, Sysmex Corporation. The report also identifies company-specific strategies related to market consolidation initiatives and analysis of their specific strengths, weaknesses, opportunities and threats.

Report Synopsis

This report by Future Market Insights (FMI) examines the ‘Liquid Biopsy Market’ for the period 2016–2026. The primary objective of the report is to offer updates and information related to market opportunities in the global liquid biopsy market.

Report Description

The global liquid biopsy market report begins by defining liquid biopsy and various types of markers used in liquid biopsy. It is followed by an overview of market dynamics of the global liquid biopsy market, which includes FMI’s analysis of key trends, drivers, restraints and opportunities, and reimbursement scenario that is influencing the growth of the liquid biopsy market. It also includes an insight into case-studies and product pipeline. Impact analysis of key growth drivers and restraints based on a weighted average model have been included in the global liquid biopsy market report after detailed analysis of individual regions to better equip readers with meaningful insights on ongoing developments in the oncology market.

The primary factors fuelling demand for liquid biopsy diagnostic tests are growing incidences of lung, gastrointestinal and breast cancer. Other factors driving demand for liquid biopsy tests are increasing inclination of oncologists and physician to opt for non-invasive diagnostic procedures, reluctance of the patients to go painful biopsies and increase in the demand of personalized medicine.  Whereas increasing number of test launches and entry of regional players also drives the market for liquid biopsy tests. However, a primary factor hampering growth of the liquid biopsy market is its penetration owing lower awareness of blood tests to detect cancer.

Based on market type, the market has been segmented into circulating tumour cells (CTCs), Circulating tumour Nucleic Acids (ctNA) and exosomes. A detailed analysis has been provided for these segment in terms of market size, Y-o-Y growth rate, absolute $ opportunity and BPS analysis.

Based on sample type, the market has been segmented into blood, urine and others (plasma, saliva, CSF). Our analysis predicts that biopsies through blood samples would increase at a very fast pace, increasing the number of blood diagnostic test to detect cancer is expected to contribute significantly to increasing demand for liquid biopsies the forecast period.

Based on the disease indication the liquid biopsy market has been segmented into lung cancer, gastrointestinal cancer, prostate cancer, breast cancer, colorectal cancer, leukemia and others.  Lung cancer is expected to expand at a higher CAGR, due to increasing prevalence of lung cancer over the forecast period. Further, based on end-user segmentation, the market is segmented into hospitals, cancer institutes, academic institutes and diagnostic centres. Increasing commercialization of liquid biopsy test is expected to increase the revenue generation of liquid biopsies from hospitals and diagnostic centres surgery. This trend is expected to be particularly prominent in countries where access to healthcare services is increasing especially in APEJ

The next section of the report highlights liquid biopsy market by region and provides market outlook for 2016–2026. The report also discusses key regional trends contributing to the revenue growth of the liquid biopsy tests worldwide, as well as analyses the impact of drivers and restraints in each region. Key regions assessed in this report include North America, Latin America, Western Europe, Eastern Europe, Asia Pacific Excluding Japan (APEJ), Japan and Middle East & Africa (MEA).

The above sections—by marker type, sample type, disease indication, end users and region—evaluate the present scenario and growth prospects of the liquid biopsy tests market for 2016–2026. We have considered 2015 as the base year and provided data for the forecast period, i.e., 2016–2026.

To ascertain liquid biopsy tests market size, we have also considered revenue generated by companies in liquid biopsy market space. The forecast presented here assesses the total revenue by value across the liquid biopsy market. In order to offer an accurate forecast, we started by sizing up the current market, which forms the basis of how the liquid biopsy market is expected to develop in the future. Given the characteristics of the market, we triangulated the outcome of three different types of analysis based on supply side, downstream industry demand, and the economic envelope.

In addition, it is imperative to note that in an ever-fluctuating global economy, we not only conduct forecasts in terms of CAGR, but also analyse it based on key parameters such as year-on-year (Y-o-Y) growth rates to understand the predictability of the market, and to identify the right opportunities across the global liquid biopsy market.

The liquid biopsy market segments in terms of marker type, sample type, disease indication, end user, and regions. These segments are analysed in terms of Basis Point Share (BPS) to understand individual segment’s relative contributions to market growth. This detailed level of information is important for identifying various key trends in the liquid biopsy market.

Another key feature of this report is the analysis of key segments in terms of absolute dollar opportunity. This is overlooked while forecasting the market. However, absolute dollar opportunity is critical for assessing the level of opportunity that a provider can look to achieve, as well as to identify potential resources from a sales and delivery perspective, in the global liquid biopsy market.

To understand key growth segments in terms of growth and adoption for liquid biopsy tests globally, Future Market Insights developed the liquid biopsy market ‘Attractiveness Index’. The resulting index is expected to help providers identify real market opportunities in the overall oncology market.

In the final section of the report on the global liquid biopsy market, ‘Competitive Landscape’ is included to provide report audiences with a dashboard view, based on categories of test developers in the liquid biopsy market space and key differentiators. Key categories of providers covered in the report are companies developing liquid biopsy tests. This section is primarily designed to provide clients with an objective and detailed comparative assessment of key providers specific to a market segment in the liquid biopsy value chain and the potential players for the same. Report audiences can gain segment-specific company insights to identify and evaluate key competitors based on in-depth assessment of capabilities and successes in liquid biopsy marketplace.

Detailed profiles of the liquid biopsy tests developing companies are also included in the scope of the report to evaluate their long- and short-term strategies, key offerings, SWOT analysis, and recent developments in the global liquid biopsy market.

Key competitors covered in terms of liquid biopsy test developing companies BIOCEPT, INC., Qiagen N.V., Trovagene, Inc., Janssen Global Services, LLC, MDxHealth SA, Natera, Inc., F. Hoffmann-La Roche Ltd., Silicon Biosystems, Pathway Genomics Corporation, Sysmex Corporation.

Key Segments Covered

  • By Marker Type
    • CTCs (Circulating tumour Cells)
    • ctNA (Circulating tumour Nucleic Acids)
    • Exosomes
  • By Sample Type
    • Blood
    • Urine
    • Others (Plasma, Saliva, CSF)
  • By Disease Indication
    • Lung Cancer
    • Gastrointestinal Cancer
    • Prostate Cancer
    • Breast Cancer
    • Colorectal Cancer
    • Leukemia
    • Others
  • By End-User
    • Hospitals
    • Cancer Institutes
    • Academic Institutes
    • Diagnostic Centers

Key Regions/Countries Covered

  • North America
    • U.S.
    • Canada
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Western Europe
    • U.K.
    • Germany
    • France
    • Spain
    • Italy
    • Nordic
    • BENELUX
    • Rest of Western Europe
  • Eastern Europe
    • Russia
    • Poland
    • Rest of Eastern Europe
  • Asia Pacific Ex. Japan (APEJ)
    • China
    • India
    • Australia and New Zealand
    • ASEAN
    • Rest of APAC
  • Japan
  • Middle East & Africa
    • GCC
    • South Africa
    • Rest of MEA

Key Companies

  • BIOCEPT, INC.
  • Qiagen N.V.
  • Trovagene, Inc.
  • Janssen Global Services, LLC
  • MDxHealth SA
  • Natera, Inc.
  • Hoffmann-La Roche Ltd.
  • Silicon Biosystems
  • Pathway Genomics Corporation
  • Sysmex Corporation

Liquid Biopsy Market Reports - Table of Contents

1. Executive Summary

2. Assumptions and Acronyms

3. Research Methodology

4. Liquid Biopsy Market Overview

4.1. Introduction

4.1.1. Liquid Biopsy Market Definition

4.1.2. Liquid Biopsy Market Taxonomy

4.2. Liquid Biopsy Market Dynamics

4.2.1. Drivers

4.2.2. Restraints

4.2.3. Opportunity

4.3. Regional Cancer Epidemiology

4.4. Reimbursement Scenario

4.5. Pipeline Assessment, By Products 

4.6. Product Penetration and Pricing Impact 

4.7. Revenue Potential Liquid Biopsy 

4.8. Case Studies

5. Global Liquid Biopsy Market Forecast

5.1. Market Value (US$ Mn) Forecast

5.1.1. Y-o-Y Growth Projections

5.1.2. Absolute $ Opportunity

5.2. Liquid Biopsy Market Trends

5.3. Global Liquid Biopsy Market Snapshot (2015)

5.3.1. Market Share, By Sample Type 

5.3.2. Market Share, By Disease Indication 

5.3.3. Market Share, By Marker Type 

5.3.4. Market Share, By End User 

6. Global Liquid Biopsy Market Analysis, By Sample Type 

6.1. Introduction

6.1.1. Y-o-Y Growth Comparison, By Sample Type 

6.1.2. Market Share & Basis Point (BPS) Analysis, By Sample Type 

6.2. Market Forecast, By Sample Type 

6.2.1. Blood 

6.2.1.1. Absolute $ Opportunity

6.2.1.2. Market Value (US$ Mn) Forecast

6.2.2. Urine

6.2.2.1. Absolute $ Opportunity

6.2.2.2. Market Value (US$ Mn) Forecast

6.2.3. Others (Plasma, Saliva, CSF)

6.2.3.1. Absolute $ Opportunity

6.2.3.2. Market Value (US$ Mn) Forecast

6.3. Market Attractiveness Analysis, By Sample Type 

7. Global Liquid Biopsy Market Analysis, By Marker Type 

7.1. Introduction

7.1.1. Y-o-Y Growth Comparison, By Marker Type 

7.1.2. Market Share & Basis Point (BPS) Analysis, By Marker Type 

7.2. Market Forecast, By Marker Type 

7.2.1. CTCs (circulating tumor cells)

7.2.1.1. Absolute $ Opportunity

7.2.1.2. Market Value (US$ Mn) Forecast

7.2.2.  ctNA (circulating tumor nucleic acids)

7.2.2.1. Absolute $ Opportunity

7.2.2.2. Market Value (US$ Mn) Forecast

7.2.3. Exosomes

7.2.3.1. Absolute $ Opportunity

7.2.3.2. Market Value (US$ Mn) Forecast

7.3. Market Attractiveness Analysis, By Marker Type 

8. Global Liquid Biopsy Market Analysis, By End User 

8.1. Introduction

8.1.1. Y-o-Y Growth Comparison, By End User 

8.1.2. Market Share & Basis Point (BPS) Analysis, By End User 

8.2. Market Forecast, By End User 

8.2.1. Hospitals 

8.2.1.1. Absolute $ Opportunity

8.2.1.2. Market Value (US$ Mn) Forecast

8.2.2. Academic Institutes 

8.2.2.1. Absolute $ Opportunity

8.2.2.2. Market Value (US$ Mn) Forecast

8.2.3. Cancer Institutes 

8.2.3.1. Absolute $ Opportunity

8.2.3.2. Market Value (US$ Mn) Forecast

8.2.4. Diagnostic Centers

8.2.4.1. Absolute $ Opportunity

8.2.4.2. Market Value (US$ Mn) Forecast

8.3. Market Attractiveness Analysis, By End User 

9. Global Liquid Biopsy Market Analysis, By Disease Indication 

9.1. Introduction

9.1.1. Y-o-Y Growth Comparison, By Disease Indication 

9.1.2. Market Share & Basis Point (BPS) Analysis, By Disease Indication 

9.2. Market Forecast, By Disease Indication 

9.2.1. Lung Cancer 

9.2.1.1. Absolute $ Opportunity

9.2.1.2. Market Value (US$ Mn) Forecast

9.2.2. Leukemia 

9.2.2.1. Absolute $ Opportunity

9.2.2.2. Market Value (US$ Mn) Forecast

9.2.3. Gastrointestinal Cancer

9.2.3.1. Absolute $ Opportunity

9.2.3.2. Market Value (US$ Mn) Forecast

9.2.4. Breast Cancer

9.2.4.1. Absolute $ Opportunity

9.2.4.2. Market Value (US$ Mn) Forecast

9.2.5. Prostate Cancer

9.2.5.1. Absolute $ Opportunity

9.2.5.2. Market Value (US$ Mn) Forecast

9.2.6. Colorectal Cancer

9.2.6.1. Absolute $ Opportunity

9.2.6.2. Market Value (US$ Mn) Forecast

9.2.7. Others

9.2.7.1. Absolute $ Opportunity

9.2.7.2. Market Value (US$ Mn) Forecast

9.3. Market Attractiveness Analysis, By Disease Indication 

10. Global Liquid Biopsy Market Analysis, By Region

10.1. Introduction

10.1.1. Y-o-Y Growth Projections, By Region

10.1.2. Market Share & Basis Point (BPS) Analysis, By Region

10.2. Market Forecast, By Region

10.2.1. North America Market Value (US$ Mn) Forecast

10.2.2. Latin America Market Value (US$ Mn) Forecast

10.2.3. Western Europe Market Value (US$ Mn) Forecast

10.2.4. Eastern Europe Market Value (US$ Mn) Forecast

10.2.5. APEJ Market Value (US$ Mn) Forecast

10.2.6. Japan Market Value (US$ Mn) Forecast

10.2.7. Middle East and Africa Market Value (US$ Mn) Forecast

10.3. Regional Attractiveness Analysis

11. North America Liquid Biopsy Market Analysis

11.1. Introduction

11.1.1. Y-o-Y Growth Projections, By Country

11.1.2. Market Share & Basis Point (BPS) Analysis, By Country

11.2. Key Trends

11.3. North America Market Forecast

11.3.1. Market Value (US$ Mn) Forecast, By Country

11.3.1.1. U.S. Absolute $ Opportunity

11.3.1.2. Canada Absolute $ Opportunity

11.3.2. Market Value (US$ Mn) Forecast, By Sample Type 

11.3.2.1. Blood 

11.3.2.2. Urine

11.3.2.3. Others (Plasma, Saliva, CSF)

11.3.3. Market Value (US$ Mn) Forecast, By Marker Type 

11.3.3.1. CTCs (circulating tumor cells)

11.3.3.2. ctNA (circulating tumor nucleic acids)

11.3.3.3. Exosomes

11.3.4. Market Value (US$ Mn) Forecast, By End User 

11.3.4.1. Hospitals 

11.3.4.2. Academic Institutes 

11.3.4.3. Cancer Institutes 

11.3.4.4. Diagnostic Centers

11.3.5. Market Value (US$ Mn) Forecast, By Disease Indication 

11.3.5.1. Lung Cancer 

11.3.5.2. Leukemia 

11.3.5.3. Gastrointestinal Cancer

11.3.5.4. Breast Cancer

11.3.5.5. Prostate Cancer

11.3.5.6. Colorectal Cancer

11.3.5.7. Others

11.5. Market Attractiveness Analysis

11.5.1. By Country

11.5.2. By Sample Type 

11.5.3. By Disease Indication 

11.5.4. By Marker Type 

11.5.5. By End User 

11.6. Drivers & Restraints: Impact Analysis

12. Latin America Liquid Biopsy Market Analysis

12.1. Introduction

12.1.1. Y-o-Y Growth Projections, By Country

12.1.2. Market Share & Basis Point (BPS) Analysis, By Country

12.2. Key Trends

12.3. Latin America Market Forecast

12.3.1. Market Value (US$ Mn) Forecast, By Country

12.3.1.1. Brazil Absolute $ Opportunity

12.3.1.2. Mexico Absolute $ Opportunity

12.3.1.3. Rest of Latin America Absolute $ Opportunity

12.3.2. Market Value (US$ Mn) Forecast, By Sample Type 

12.3.2.1. Blood 

12.3.2.2. Urine

12.3.2.3. Others (Plasma, Saliva, CSF)

12.3.3. Market Value (US$ Mn) Forecast, By Marker Type 

12.4.3.1. CTCs (circulating tumor cells)

12.4.3.2. ctNA (circulating tumor nucleic acids)

12.4.3.3. Exosomes 

12.3.4. Market Value (US$ Mn) Forecast, By End User 

12.3.4.1. Hospitals 

12.3.4.2. Academic Institutes 

12.3.4.3. Cancer Institutes 

12.3.4.4. Diagnostic Centers

12.3.5. Market Value (US$ Mn) Forecast, By Disease Indication 

12.3.5.1. Lung Cancer 

12.3.5.2. Leukemia 

12.3.5.3. Gastrointestinal Cancer

12.3.5.4. Breast Cancer

12.3.5.5. Prostate Cancer

12.3.5.6. Colorectal Cancer

12.3.5.7. Others

12.4. Market Attractiveness Analysis

12.4.1. By Country

12.4.2. By Sample Type 

12.4.3. By Disease Indication 

12.4.4. By Marker Type 

12.4.5. By End User 

12.5. Drivers & Restraints: Impact Analysis

13. Western Europe Liquid Biopsy Market Analysis

13.1. Introduction

13.1.1. Y-o-Y Growth Projections, By Country

13.1.2. Market Share & Basis Point (BPS) Analysis, By Country

13.2. Key Trends

13.3. Western Europe Market Forecast

13.3.1. Market Value (US$ Mn) Forecast, By Country

13.3.1.1. Germany Absolute $ Opportunity

13.3.1.2. France Absolute $ Opportunity

13.3.1.3. U.K. Absolute $ Opportunity

13.3.1.4. Spain Absolute $ Opportunity

13.3.1.5. Italy Absolute $ Opportunity

13.3.1.6. Rest of Western Europe Absolute $ Opportunity

13.3.2. Market Value (US$ Mn) Forecast, By Sample Type 

13.4.2.1. Blood 

13.4.2.2. Urine

13.3.2.3. Others (Plasma, Saliva, CSF)

13.3.3. Market Value (US$ Mn) Forecast, By Marker Type 

13.3.3.1. CTCs (circulating tumor cells)

13.3.3.2. ctNA (circulating tumor nucleic acids)

13.3.3.3. Exosomes

13.3.4. Market Value (US$ Mn) Forecast, By End User 

13.3.4.1. Hospitals 

13.3.4.2. Academic Institutes 

13.3.4.3. Cancer Institutes 

13.3.4.4. Diagnostic Centers

13.3.5. Market Value (US$ Mn) Forecast, By Disease Indication 

13.3.5.1. Lung Cancer 

13.4.5.2. Leukemia 

13.4.5.3. Gastrointestinal Cancer

13.4.5.4. Breast Cancer

13.4.5.5. Prostate Cancer

13.4.5.6. Colorectal Cancer

13.4.5.7. Others

13.4. Market Attractiveness Analysis

13.4.1. By Country

13.4.2. By Sample Type 

13.4.3. By Disease Indication 

13.4.4. By Marker Type 

13.4.5. By End User 

13.5. Drivers & Restraints: Impact Analysis

14. Eastern Europe Liquid Biopsy Market Analysis

14.1. Introduction

14.1.1. Y-o-Y Growth Projections, By Country

14.1.2. Market Share & Basis Point (BPS) Analysis, By Country

14.2. Key Trends

14.3. Eastern Europe Market Forecast

14.3.1. Market Value (US$ Mn) Forecast, By Country

14.3.1.1. Russia Absolute $ Opportunity

14.3.1.2. Poland Absolute $ Opportunity

14.3.1.3. Rest of Eastern Europe Absolute $ Opportunity

14.3.2. Market Value (US$ Mn) Forecast, By Sample Type 

14.3.2.1. Blood 

14.3.2.2. Urine

14.3.2.3. Others (Plasma, Saliva, CSF)

14.4.3. Market Value (US$ Mn) Forecast, By Marker Type 

14.4.3.1. CTCs (circulating tumor cells)

14.4.3.2. ctNA (circulating tumor nucleic acids)

14.4.3.3. Exosomes

14.4.4. Market Value (US$ Mn) Forecast, By End User 

14.4.4.1. Hospitals 

14.4.4.2. Academic Institutes 

14.4.4.3. Cancer Institutes 

14.4.4.4. Diagnostic Centers

14.4.5. Market Value (US$ Mn) Forecast, By Disease Indication 

14.4.5.1. Lung Cancer 

14.4.5.2. Leukemia 

14.4.5.3. Gastrointestinal Cancer

14.4.5.4. Breast Cancer

14.4.5.5. Prostate Cancer

14.4.5.6. Colorectal Cancer

14.4.5.7. Others

14.5. Market Attractiveness Analysis

14.5.1. By Country

14.5.2. By Sample Type

14.5.3. By Disease Indication 

14.5.4. By Marker Type 

14.5.5. By End User

15. APEJ Liquid Biopsy Market Analysis

15.1. Introduction

15.1.1. Y-o-Y Growth Projections, By Country

15.1.2. Market Share & Basis Point (BPS) Analysis, By Country

15.2. Key Trends

15.3. APEJ Market Forecast

15.3.1. Market Value (US$ Mn) Forecast, By Country

14.3.1.1. China Absolute $ Opportunity

14.3.1.2. India Absolute $ Opportunity

14.3.1.3. Australia & New Zealand Absolute $ Opportunity

14.3.1.4. ASEAN Absolute $ Opportunity

14.3.1.5. Rest of APEJ Absolute $ Opportunity

15.3.2. Market Value (US$ Mn) Forecast, By Sample Type 

15.3.2.1. Blood 

15.3.2.2. Urine

15.3.2.3. Others (Plasma, Saliva, CSF)

15.4.3. Market Value (US$ Mn) Forecast, By Marker Type 

15.4.3.1. CTCs (circulating tumor cells)

15.4.3.2. ctNA (circulating tumor nucleic acids)

15.4.3.3. Exosomes

15.4.4. Market Value (US$ Mn) Forecast, By End User 

15.4.4.1. Hospitals 

15.4.4.2. Academic Institutes 

15.4.4.3. Cancer Institutes 

15.4.4.4. Diagnostic Centers

15.4.5. Market Value (US$ Mn) Forecast, By Disease Indication 

15.4.5.1. Lung Cancer 

15.4.5.2. Leukemia 

15.4.5.3. Gastrointestinal Cancer

15.4.5.4. Breast Cancer

15.4.5.5. Prostate Cancer

15.4.5.6. Colorectal Cancer

15.4.5.7. Others

15.5. Market Attractiveness Analysis

15.5.1. By Country

15.5.2. By Sample Type 

15.5.3. By Disease Indication 

15.5.4. By Marker Type 

15.5.5. By End User 

15.6. Drivers & Restraints: Impact Analysis

16. Japan Liquid Biopsy Market Analysis

16.1. Introduction

16.2. Key Trends

16.3. Japan Market Forecast

16.3.1. Market Value (US$ Mn) Forecast, By Sample Type 

16.3.1.1. Blood 

16.3.1.2. Urine

16.4.1.3. Others (Plasma, Saliva, CSF)

16.3.2. Market Value (US$ Mn) Forecast, By Marker Type 

16.3.2.1. CTCs (circulating tumor cells)

16.3.2.2. ctIndication (circulating tumor nucleic acids)

16.3.2.3. Exosomes

16.3.3. Market Value (US$ Mn) Forecast, By End User 

16.3.3.1. Hospitals 

16.3.3.2. Academic Institutes 

16.3.3.3. Cancer Institutes 

16.3.3.4. Diagnostic Centers

16.3.4. Market Value (US$ Mn) Forecast, By Disease Indication 

16.3.4.1. Lung Cancer 

16.3.4.2. Leukemia 

16.3.4.3. Gastrointestinal Cancer

16.3.4.4. Metastatic Breast Cancer

16.3.4.5. Metastatic Prostate Cancer

16.3.4.6. Metastatic Colorectal Cancer

16.3.4.7. Others

16.4. Market Attractiveness Analysis

16.4.1. By Sample Type 

16.4.2. By Disease Indication 

16.4.3. By Marker Type 

16.4.4. By End User 

16.5. Drivers & Restraints: Impact Analysis

17. Middle East and Africa Liquid Biopsy Market Analysis

17.1. Introduction

17.1.1. Y-o-Y Growth Projections, By Country

17.1.2. Market Share & Basis Point (BPS) Analysis, By Country

17.2. Key Trends

17.3. Middle East and Africa Market Forecast

17.3.1. Market Value (US$ Mn) Forecast, By Country

17.3.1.1. GCC Countries Absolute $ Opportunity

17.3.1.2. South Africa Absolute $ Opportunity

17.3.1.3. Rest of MEA Absolute $ Opportunity

17.3.2. Market Value (US$ Mn) Forecast, By Sample Type 

17.3.2.1. Blood 

17.3.2.2. Urine

17.3.2.3. Others (Plasma, Saliva, CSF)

17.3.3. Market Value (US$ Mn) Forecast, By Marker Type 

17.3.3.1. CTCs (circulating tumor cells)

17.3.3.2. ctNA (circulating tumor nucleic acids)

17.3.3.3. Exosomes

17.3.4. Market Value (US$ Mn) Forecast, By End User 

17.3.4.1. Hospitals 

17.3.4.2. Academic Institutes 

17.3.4.3. Cancer Institutes 

17.3.4.4. Diagnostic Centers

17.3.5. Market Value (US$ Mn) Forecast, By Disease Indication 

17.3.5.1. Lung Cancer 

17.3.5.2. Leukemia 

17.3.5.3. Gastrointestinal Cancer

17.3.5.4. Metastatic Breast Cancer

17.3.5.5. Metastatic Prostate Cancer

17.3.5.6. Metastatic Colorectal Cancer

17.3.5.7. Others

17.4. Market Attractiveness Analysis

17.4.1. By Country

17.4.2. By Sample Type 

17.4.3. By Disease Indication 

17.4.4. By Marker Type 

17.4.5. By End User 

17.5. Drivers & Restraints: Impact Analysis

18. Competition Landscape

18.1. Competition Dashboard

18.2. Company Profiles Inclusions

18.2.1. Revenue

18.2.2. Products/Brand Offerings

18.2.3. Key developments

18.2.4. SWOT Analysis

18.3. Company Profiled

18.3.1. BIOCEPT, INC.

18.3.2. Qiagen N.V.

18.3.3. Trovagene, Inc

18.3.4. Janssen Global Services, LLC

18.3.5. MDxHealth SA

18.3.6. Natera, Inc

18.3.7. F. Hoffmann-La Roche Ltd

18.3.8. Silicon Biosystems

18.3.9. Pathway Genomics Corporation

18.3.10. Sysmex Corporation

Liquid Biopsy Market Reports - List of Tables

Table 01: Global Liquid Biopsy Market Value Forecast By Sample Type, 2016–2026

Table 02: Global Liquid Biopsy Market Value Forecast By Marker Type, 2016–2026

Table 03: Global Liquid Biopsy Market Value Forecast By End User, 2016–2026

Table 04: Global Liquid Biopsy Market Value Forecast By Disease Indication, 2016–2026

Table 05: Global Liquid Biopsy Market Value Forecast By Region, 2016–2026

Table 06: North America Liquid Biopsy Market Value Forecast By Country, 2016–2026

Table 07: North America Liquid Biopsy Market Value Forecast By Sample Type, 2016–2026

Table 08: North America Liquid Biopsy Market Value Forecast By Marker Type, 2016–2026

Table 09: North America Liquid Biopsy Market Value Forecast By End User, 2016–2026

Table 10: North America Liquid Biopsy Market Value Forecast By Disease Indication, 2016–2026

Table 11: Latin America Liquid Biopsy Market Value Forecast By Country, 2016–2026

Table 12: Latin America Liquid Biopsy Market Value Forecast By Sample Type, 2016–2026

Table 13: Latin America Liquid Biopsy Market Value Forecast By Marker Type, 2016–2026

Table 14: Latin America Liquid Biopsy Market Value Forecast By End User, 2016–2026

Table 15: Latin America Liquid Biopsy Market Value Forecast By Disease Indication, 2016–2026

Table 16: Western Europe Liquid Biopsy Market Value Forecast By Country, 2016–2026

Table 17: Western Europe Liquid Biopsy Market Value Forecast By Sample Type, 2016–2026

Table 18: Western Europe Liquid Biopsy Market Value Forecast By Marker Type, 2016–2026

Table 19: Western Europe Liquid Biopsy Market Value Forecast By End User, 2016–2026

Table 20: Western Europe Liquid Biopsy Market Value Forecast By Disease Indication, 2016–2026

Table 21: Eastern Europe Liquid Biopsy Market Value Forecast By Country, 2016–2026

Table 22: Eastern Europe Liquid Biopsy Market Value Forecast By Sample Type, 2016–2026

Table 23: Eastern Europe Liquid Biopsy Market Value Forecast By Marker Type, 2016–2026

Table 24: Eastern Europe Liquid Biopsy Market Value Forecast By End User, 2016–2026

Table 25: Eastern Europe Liquid Biopsy Market Value Forecast By Disease Indication, 2016–2026

Table 26: APEJ Liquid Biopsy Market Value Forecast By Country, 2016–2026

Table 27: APEJ Liquid Biopsy Market Value Forecast By Sample Type, 2016–2026

Table 28: APEJ Liquid Biopsy Market Value Forecast By Marker Type, 2016–2026

Table 29: APEJ Liquid Biopsy Market Value Forecast By End User, 2016–2026

Table 30: APEJ Liquid Biopsy Market Value Forecast By Disease Indication, 2016–2026

Table 31: Japan Liquid Biopsy Market Value Forecast By Sample Type, 2016–2026

Table 32: Japan Liquid Biopsy Market Value Forecast By Marker Type, 2016–2026

Table 33: Japan Liquid Biopsy Market Value Forecast By End User, 2016–2026

Table 34: Japan Liquid Biopsy Market Value Forecast By Disease Indication, 2016–2026

Table 35: MEA Liquid Biopsy Market Value Forecast By Country, 2016–2026

Table 36: MEA Liquid Biopsy Market Value Forecast By Sample Type, 2016–2026

Table 37: MEA Liquid Biopsy Market Value Forecast By Marker Type, 2016–2026

Table 38: MEA Liquid Biopsy Market Value Forecast By End User, 2016–2026

Table 39: MEA Liquid Biopsy Market Value Forecast By Disease Indication, 2016–2026

Liquid Biopsy Market Reports - List of Figures

Figure 01: Global Liquid Biopsy Market Share Analysis (%) By Sample Type, 2016 & 2026

Figure 02: Global Liquid Biopsy Market Y-o-Y growth (%) By Sample Type, 2016–2026

Figure 03: Global Liquid Biopsy Market Attractiveness Analysis By Sample Type, 2016–2026

Figure 04: Global Liquid Biopsy Market Value (US$ Mn) & Y-o-Y Growth (%) By Blood Sample Type Segment, 2016–2026

Figure 05: Global Liquid Biopsy Market Absolute $ Opportunity (US$ Mn) By Blood Sample Type Segment, 2016–2026

Figure 06: Global Liquid Biopsy Market Value (US$ Mn) & Y-o-Y Growth (%) By Urine Sample Type Segment, 2016–2026

Figure 07: Global Liquid Biopsy Market Absolute $ Opportunity (US$ Mn) By Urine Sample Type Segment, 2016–2026

Figure 08: Global Liquid Biopsy Market Value (US$ Mn) & Y-o-Y Growth (%) By Others (Plasma, Saliva, CSF) Sample Type Segment, 2016–2026

Figure 09: Global Liquid Biopsy Market Absolute $ Opportunity (US$ Mn) By Others (Plasma, Saliva, CSF) Sample Type Segment, 2016–2026

Figure 10: Global Liquid Biopsy Market Share Analysis (%) By Marker Type, 2016 & 2026

Figure 11: Global Liquid Biopsy Market Y-o-Y growth (%) By Marker Type, 2016–2026

Figure 12: Global Liquid Biopsy Market Attractiveness Analysis By Marker Type, 2016–2026

Figure 13: Global Liquid Biopsy Market Value (US$ Mn) & Y-o-Y Growth (%) By CTCs Marker Type Segment, 2016–2026

Figure 14: Global Liquid Biopsy Market Absolute $ Opportunity (US$ Mn) By CTCs Marker Type Segment, 2016–2026

Figure 15: Global Liquid Biopsy Market Value (US$ Mn) & Y-o-Y Growth (%) By CtNA Marker Type Segment, 2016–2026

Figure 16: Global Liquid Biopsy Market Absolute $ Opportunity (US$ Mn) By ctNA Marker Type Segment, 2016–2026

Figure 17: Global Liquid Biopsy Market Value (US$ Mn) & Y-o-Y Growth (%) By Exosomes Marker Type Segment, 2016–2026

Figure 18: Global Liquid Biopsy Market Absolute $ Opportunity (US$ Mn) By Exosomes Marker Type Segment, 2016–2026

Figure 19: Global Liquid Biopsy Market Share Analysis (%) By End User, 2016 & 2026

Figure 20: Global Liquid Biopsy Market Y-o-Y growth (%) By End User, 2016–2026

Figure 21: Global Liquid Biopsy Market Attractiveness Analysis By End User, 2016–2026

Figure 22: Global Liquid Biopsy Market Value (US$ Mn) & Y-o-Y Growth (%) By Hospitals End User Segment, 2016–2026

Figure 23: Global Liquid Biopsy Market Absolute $ Opportunity (US$ Mn) By Hospitals End User Segment, 2016–2026

Figure 24: Global Liquid Biopsy Market Value (US$ Mn) & Y-o-Y Growth (%) By Cancer Institutes End User Segment, 2016–2026

Figure 25: Global Liquid Biopsy Market Absolute $ Opportunity (US$ Mn) By Cancer Institutes End User Segment, 2016–2026

Figure 26: Global Liquid Biopsy Market Value (US$ Mn) & Y-o-Y Growth (%) By Academic Institutes End User Segment, 2016–2026

Figure 27: Global Liquid Biopsy Market Absolute $ Opportunity (US$ Mn) By Academic Institutes End User Segment, 2016–2026

Figure 28: Global Liquid Biopsy Market Value (US$ Mn) & Y-o-Y Growth (%) By Diagnostics Centers End User Segment, 2016–2026

Figure 29: Global Liquid Biopsy Market Absolute $ Opportunity (US$ Mn) By Diagnostics Centers End User Segment, 2016–2026

Figure 30: Global Liquid Biopsy Market Share Analysis (%) By Disease Indication, 2016 & 2026

Figure 31: Global Liquid Biopsy Market Y-o-Y growth (%) By Disease Indication, 2016–2026

Figure 32: Global Liquid Biopsy Market Attractiveness Analysis By Disease Indication, 2016–2026

Figure 33: Global Liquid Biopsy Market Value (US$ Mn) & Y-o-Y Growth (%) By Lung Cancer Disease Indication Segment, 2016–2026

Figure 34: Global Liquid Biopsy Market Absolute $ Opportunity (US$ Mn) By Lung Cancer Disease Indication Segment, 2016–2026

Figure 35: Global Liquid Biopsy Market Value (US$ Mn) & Y-o-Y Growth (%) By Gastrointestinal Cancer Disease Indication Segment, 2016–2026

Figure 36: Global Liquid Biopsy Market Absolute $ Opportunity (US$ Mn) By Gastrointestinal Cancer Disease Indication Segment, 2016–2026

Figure 37: Global Liquid Biopsy Market Value (US$ Mn) & Y-o-Y Growth (%) By Prostate Cancer Disease Indication Segment, 2016–2026

Figure 38: Global Liquid Biopsy Market Absolute $ Opportunity (US$ Mn) By Prostate Cancer Disease Indication Segment, 2016–2026

Figure 39: Global Liquid Biopsy Market Value (US$ Mn) & Y-o-Y Growth (%) By Breast Cancer Disease Indication Segment, 2016–2026

Figure 40: Global Liquid Biopsy Market Absolute $ Opportunity (US$ Mn) By Breast Cancer Disease Indication Segment, 2016–2026

Figure 41: Global Liquid Biopsy Market Value (US$ Mn) & Y-o-Y Growth (%) By Colorectal Cancer Disease Indication Segment, 2016–2026

Figure 42: Global Liquid Biopsy Market Absolute $ Opportunity (US$ Mn) By Colorectal Cancer Disease Indication Segment, 2016–2026

Figure 43: Global Liquid Biopsy Market Value (US$ Mn) & Y-o-Y Growth (%) By Leukemia Disease Indication Segment, 2016–2026

Figure 44: Global Liquid Biopsy Market Absolute $ Opportunity (US$ Mn) By Leukemia Disease Indication Segment, 2016–2026

Figure 45: Global Liquid Biopsy Market Value (US$ Mn) & Y-o-Y Growth (%) By Others Cancer Disease Indication Segment, 2016–2026

Figure 46: Global Liquid Biopsy Market Absolute $ Opportunity (US$ Mn) By Others Cancer Disease Indication Segment, 2016–2026

Figure 47: Global Liquid Biopsy Market Share Analysis (%) By Region, 2016 & 2026

Figure 48: Global Liquid Biopsy Market Y-o-Y growth (%) By Region, 2016–2026

Figure 49: Global Liquid Biopsy Market Attractiveness Analysis By Region, 2016–2026

Figure 50: North America Liquid Biopsy Market Value (US$ Mn) & Y-o-Y Growth (%), 2016–2026

Figure 51: North America Liquid Biopsy Market Absolute $ Opportunity (US$ Mn), 2016–2026

Figure 53: Latin America Liquid Biopsy Market Absolute $ Opportunity (US$ Mn), 2016–2026

Figure 54: Western Europe Liquid Biopsy Market Value (US$ Mn) & Y-o-Y Growth (%), 2016–2026

Figure 55: Western Europe Liquid Biopsy Market Absolute $ Opportunity (US$ Mn), 2016–2026

Figure 56: Eastern Europe Liquid Biopsy Market Value (US$ Mn) & Y-o-Y Growth (%), 2016–2026

Figure 57: Eastern Europe Liquid Biopsy Market Absolute $ Opportunity (US$ Mn), 2016–2026

Figure 58: APEJ Liquid Biopsy Market Value (US$ Mn) & Y-o-Y Growth (%), 2016–2026

Figure 59: APEJ Liquid Biopsy Market Absolute $ Opportunity (US$ Mn), 2016–2026

Figure 60: Japan Liquid Biopsy Market Value (US$ Mn) & Y-o-Y Growth (%), 2016–2026

Figure 61: Japan Liquid Biopsy Market Absolute $ Opportunity (US$ Mn), 2016–2026

Figure 62: MEA Liquid Biopsy Market Value (US$ Mn) & Y-o-Y Growth (%), 2016–2026

Figure 63: MEA Liquid Biopsy Market Absolute $ Opportunity (US$ Mn), 2016–2026

Figure 64: North America Liquid Biopsy Market Share Analysis (%) By Country, 2016 & 2026

Figure 65: North America Liquid Biopsy Market Y-o-Y growth (%) By Country, 2016–2026

Figure 66: North America Liquid Biopsy Market Attractiveness Analysis By Country, 2016–2026

Figure 67: The U.S. Liquid Biopsy Market Value (US$ Mn) & Y-o-Y Growth (%), 2016–2026

Figure 68: The U.S. Liquid Biopsy Market Absolute $ Opportunity (US$ Mn), 2016–2026

Figure 69: Canada Liquid Biopsy Market Value (US$ Mn) & Y-o-Y Growth (%), 2016–2026

Figure 70: Canada Liquid Biopsy Market Absolute $ Opportunity (US$ Mn), 2016–2026

Figure 71: North America Liquid Biopsy Market Attractiveness Analysis By Marker Type, 2016–2026

Figure 72: North America Liquid Biopsy Market Attractiveness Analysis By End User, 2016–2026

Figure 73: North America Liquid Biopsy Market Attractiveness Analysis By Sample Type, 2016–2026

Figure 74: North America Liquid Biopsy Market Attractiveness Analysis By Disease Indication, 2016–2026

Figure 75: Latin America Liquid Biopsy Market Share Analysis (%) By Country, 2016 & 2026

Figure 76: Latin America Liquid Biopsy Market Y-o-Y growth (%) By Country, 2016–2026

Figure 77: Latin America Liquid Biopsy Market Attractiveness Analysis By Country, 2016–2026

Figure 78: Brazil Liquid Biopsy Market Value (US$ Mn) & Y-o-Y Growth (%), 2015–2026

Figure 79: Brazil Liquid Biopsy Market Absolute $ Opportunity (US$ Mn), 2016–2026

Figure 80: Mexico Liquid Biopsy Market Value (US$ Mn) & Y-o-Y Growth (%), 2015–2026

Figure 81: Mexico Liquid Biopsy Market Absolute $ Opportunity (US$ Mn), 2016–2026

Figure 82: Rest of Latin America Liquid Biopsy Market Value (US$ Mn) & Y-o-Y Growth (%), 2015–2026

Figure 83: Rest of Latin America Liquid Biopsy Market Absolute $ Opportunity (US$ Mn), 2016–2026

Figure 84: Latin America Liquid Biopsy Market Attractiveness Analysis By Marker Type, 2016–2026

Figure 85: Latin America Liquid Biopsy Market Attractiveness Analysis By End User, 2016–2026

Figure 86: Latin America Liquid Biopsy Market Attractiveness Analysis By Sample Type, 2016–2026

Figure 87: Latin America Liquid Biopsy Market Attractiveness Analysis By Disease Indication, 2016–2026

Figure 90: Western Europe Liquid Biopsy Market Share Analysis (%) By Country, 2016 & 2026

Figure 91: Western Europe Liquid Biopsy Market Y-o-Y growth (%) By Country, 2016–2026

Figure 92: Western Europe Liquid Biopsy Market Attractiveness Analysis By Country, 2016–2026

Figure 93: The U.K Liquid Biopsy Market Value (US$ Mn) & Y-o-Y Growth (%), 2015–2026

Figure 94: The U.K Liquid Biopsy Market Absolute $ Opportunity (US$ Mn), 2016–2026

Figure 95: Germany Liquid Biopsy Market Value (US$ Mn) & Y-o-Y Growth (%), 2015–2026

Figure 96: Germany Liquid Biopsy Market Absolute $ Opportunity (US$ Mn), 2016–2026

Figure 97: France Liquid Biopsy Market Value (US$ Mn) & Y-o-Y Growth (%), 2015–2026

Figure 98: France Liquid Biopsy Market Absolute $ Opportunity (US$ Mn), 2016–2026

Figure 99: Spain the liquid biopsy market Value (US$ Mn) & Y-o-Y Growth (%), 2015–2026

Figure 100: Spain the liquid biopsy market Absolute $ Opportunity (US$ Mn), 2016–2026

Figure 101: Italy Liquid Biopsy Market Value (US$ Mn) & Y-o-Y Growth (%), 2015–2026

Figure 102: Italy Liquid Biopsy Market Absolute $ Opportunity (US$ Mn), 2016–2026

Figure 103: NORDIC Liquid Biopsy Market Value (US$ Mn) & Y-o-Y Growth (%), 2015–2026

Figure 104: NORDIC Liquid Biopsy Market Absolute $ Opportunity (US$ Mn), 2016–2026

Figure 105: BENELUX Liquid Biopsy Market Value (US$ Mn) & Y-o-Y Growth (%), 2015–2026

Figure 106: BENELUX Liquid Biopsy Market Absolute $ Opportunity (US$ Mn), 2016–2026

Figure 107: Rest of Western Europe Liquid Biopsy Market Value (US$ Mn) & Y-o-Y Growth (%), 2015–2026

Figure 108: Rest of Western Europe Liquid Biopsy Market Absolute $ Opportunity (US$ Mn), 2016–2026

Figure 109: Western Europe Liquid Biopsy Market Attractiveness Analysis By Marker Type, 2016–2026

Figure 110: Western Europe Liquid Biopsy Market Attractiveness Analysis By End User, 2016–2026

Figure 111: Western Europe Liquid Biopsy Market Attractiveness Analysis By Sample Type, 2016–2026

Figure 112: Western Europe Liquid Biopsy Market Attractiveness Analysis By Disease Indication, 2016–2026

Figure 113: Eastern Europe Liquid Biopsy Market Share Analysis (%) By Country, 2016 & 2026

Figure 114: Eastern Europe Liquid Biopsy Market Y-o-Y growth (%) By Country, 2016–2026

Figure 115: Eastern Europe Liquid Biopsy Market Attractiveness Analysis By Country, 2016–2026

Figure 116: Russia Liquid Biopsy Market Value (US$ Mn) & Y-o-Y Growth (%), 2015–2026

Figure 117: Russia Liquid Biopsy Market Absolute $ Opportunity (US$ Mn), 2016–2026

Figure 118: Poland Liquid Biopsy Market Value (US$ Mn) & Y-o-Y Growth (%), 2015–2026

Figure 119: Poland Liquid Biopsy Market Absolute $ Opportunity (US$ Mn), 2016–2026

Figure 120: Rest of Eastern Europe Liquid Biopsy Market Value (US$ Mn) & Y-o-Y Growth (%), 2015–2026

Figure 121: Rest of Eastern Europe Liquid Biopsy Market Absolute $ Opportunity (US$ Mn), 2016–2026

Figure 122: Eastern Europe Liquid Biopsy Market Attractiveness Analysis By Marker Type, 2016–2026

Figure 123: Eastern Europe Liquid Biopsy Market Attractiveness Analysis By End User, 2016–2026

Figure 124: Eastern Europe Liquid Biopsy Market Attractiveness Analysis By Sample Type, 2016–2026

Figure 125: Eastern Europe Liquid Biopsy Market Attractiveness Analysis By Disease Indication, 2016–2026

Figure 126: APEJ Liquid Biopsy Market Share Analysis (%) By Country, 2016 & 2026

Figure 127: APEJ Liquid Biopsy Market Y-o-Y growth (%) By Country, 2016–2026

Figure 128: APEJ Liquid Biopsy Market Attractiveness Analysis By Country, 2016–2026

Figure 129: China Liquid Biopsy Market Value (US$ Mn) & Y-o-Y Growth (%), 2015–2026

Figure 130: China Liquid Biopsy Market Absolute $ Opportunity (US$ Mn), 2016–2026

Figure 131: India Liquid Biopsy Market Value (US$ Mn) & Y-o-Y Growth (%), 2015–2026

Figure 132: India Liquid Biopsy Market Absolute $ Opportunity (US$ Mn), 2016–2026

Figure 133: Australia & New Zealand Liquid Biopsy Market Value (US$ Mn) & Y-o-Y Growth (%), 2015–2026

Figure 134: Australia & New Zealand Liquid Biopsy Market Absolute $ Opportunity (US$ Mn), 2016–2026

Figure 135: ASEAN Liquid Biopsy Market Value (US$ Mn) & Y-o-Y Growth (%), 2015–2026

Figure 136: ASEAN Liquid Biopsy Market Absolute $ Opportunity (US$ Mn), 2016–2026

Figure 137: Rest of APEJ Liquid Biopsy Market Value (US$ Mn) & Y-o-Y Growth (%), 2015–2026

Figure 138: Rest of APEJ Liquid Biopsy Market Absolute $ Opportunity (US$ Mn), 2016–2026

Figure 139: APEJ Liquid Biopsy Market Attractiveness Analysis By Marker Type, 2016–2026

Figure 140: APEJ Liquid Biopsy Market Attractiveness Analysis By End User, 2016–2026

Figure 141: APEJ Liquid Biopsy Market Attractiveness Analysis By Sample Type, 2016–2026

Figure 142: APEJ Liquid Biopsy Market Attractiveness Analysis By Disease Indication, 2016–2026

Figure 145: Japan Liquid Biopsy Market Attractiveness Analysis By Sample Type, 2016–2026

Figure 146: Japan Liquid Biopsy Market Attractiveness Analysis By Disease Indication, 2016–2026

Figure 143: Japan Liquid Biopsy Market Attractiveness Analysis By Marker Type, 2016–2026

Figure 144: Japan Liquid Biopsy Market Attractiveness Analysis By End User, 2016–2026

Figure 147: MEA Liquid Biopsy Market Share Analysis (%) By Country, 2016 & 2026

Figure 148: MEA Liquid Biopsy Market Y-o-Y growth (%) By Country, 2016–2026

Figure 149: MEA Liquid Biopsy Market Attractiveness Analysis By Country, 2016–2026

Figure 150: GCC Countries Liquid Biopsy Market Value (US$ Mn) & Y-o-Y Growth (%), 2015–2026

Figure 151: GCC Countries Liquid Biopsy Market Absolute $ Opportunity (US$ Mn), 2016–2026

Figure 152: South Africa Liquid Biopsy Market Value (US$ Mn) & Y-o-Y Growth (%), 2015–2026

Figure 153: South Africa Liquid Biopsy Market Absolute $ Opportunity (US$ Mn), 2016–2026

Figure 154: Rest of MEA Liquid Biopsy Market Value (US$ Mn) & Y-o-Y Growth (%), 2015–2026

Figure 155: Rest of MEA Liquid Biopsy Market Absolute $ Opportunity (US$ Mn), 2016–2026

Figure 156: MEA Liquid Biopsy Market Attractiveness Analysis By Marker Type, 2016–2026

Figure 157: MEA Liquid Biopsy Market Attractiveness Analysis By End User, 2016–2026

Figure 158: MEA Liquid Biopsy Market Attractiveness Analysis By Sample Type, 2016–2026

Figure 159: MEA Liquid Biopsy Market Attractiveness Analysis By Disease Indication, 2016–2026